Overview
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide consisting of 15 amino acids, originally isolated from a protective protein found in human gastric juice. It has been studied extensively in animal models for its effects on tissue regeneration, particularly in tendons, ligaments, muscles, and the gastrointestinal tract. Research interest in BPC-157 has accelerated since 2015, with hundreds of preclinical studies examining its mechanisms of action. As of 2026, no large-scale human clinical trials have been published, and BPC-157 is sold strictly for research use only.
Mechanism
In preclinical studies, BPC-157 appears to promote angiogenesis (new blood vessel formation), modulate nitric oxide synthesis, and accelerate collagen deposition. It has demonstrated stability in gastric juice, which is unusual for peptides and supports a wide range of administration routes in research contexts.
Research Areas
Side Effects (Preclinical)
- – Mild injection-site irritation in animal studies
- – No serious adverse effects reported in published preclinical research
Cautions
- – Strictly research use only — not approved for human consumption
- – No long-term safety data in humans
- – FDA placed BPC-157 in Category 2 of the 503A bulks list in 2023
Menopause & Women's Health Relevance
Joint pain and musculoskeletal discomfort are among the most commonly reported — and least discussed — symptoms of menopause, affecting over 50% of women in the transition. BPC-157's preclinical data on tendon, ligament, and cartilage repair makes it a researched option for connective tissue health. GI symptoms also worsen at menopause due to estrogen's role in gut motility and the gut-brain axis.
What the research shows
BPC-157 is one of the most-studied synthetic peptides in the preclinical literature, with the majority of research conducted by Sikiric and colleagues at the University of Zagreb. Studies have consistently shown accelerated healing of tendon, ligament, and muscle tissue in rodent models.
The peptide’s stability in gastric juice distinguishes it from many other peptides. Most peptides degrade rapidly in the acidic environment of the stomach, but BPC-157 retains activity, which is why oral administration routes have been explored in research settings alongside subcutaneous injection.
Regulatory context
In 2023, the FDA added BPC-157 to the Category 2 substances list under the 503A compounding rules, effectively restricting compounding pharmacies from including it in preparations. This regulatory action has had no impact on its status as a research compound — it remains available for in-vitro and laboratory research use.
Vendor pricing
Current pricing across verified vendors, sorted by $/mg:
References
- Pharmacological investigation of the stable gastric pentadecapeptide BPC 157 — Sikiric et al. (2018)
- BPC 157 and standard angiogenic growth factors — Sikiric et al. (2014)